Sector ratings Protalix BioTherapeutics, Inc.

Stocks

Market Closed - NYSE 16:00:00 2026-09-03 EDT			5-day change	1st Jan Change
2.620 ^USD	+1.16%		+0.38%	+45.56%

08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PROTALIX BIOTHERAPEUTICS, INC.	209M	-	-	-	-
ELI LILLY AND COMPANY	1,034B		A
JOHNSON & JOHNSON	663B	-	BBB	-	-
ABBVIE INC.	462B		AA		-
ROCHE HOLDING AG	344B		AA
NOVARTIS AG	307B		AAA
ASTRAZENECA PLC	251B		A
AMGEN INC.	239B		A
NOVO NORDISK A/S	207B		A
GILEAD SCIENCES, INC.	186B		AA
PFIZER INC.	165B		A
VERTEX PHARMACEUTICALS INCORPORATED	141B		AA
BRISTOL-MYERS SQUIBB COMPANY	138B		A
SANOFI	107B		AA
GSK PLC	101B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	70.85B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	58.62B		AA
BAYER AG	56.01B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	44.63B		AA
HALEON PLC	43.54B		AA
Average	230.99B		AA
Weighted average by Cap.			AA